Business
Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information
About this update from Castle Biosciences, Inc.
[{"type":"text","content":" FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced poster presentations with data on two of its skin cancer gene expression profile tests at the 18th Annual Winter Clinical Dermatology Conference, taking place virtually from Jan. 15 – 24, 2021.\n\nPresident and chief executive officer, Derek Maetzold, will also participate in the meeting’s “2021 View for Dermatology Industry Panel,” scheduled to take place on Saturday, Jan. 23, from 2:10 p.m. – 2:50 p.m. Eastern time.\n\nPoster information is as follows:\n\nDecisionDx®-Melanoma:\n\nThe virtual poster is entitled, “Identifying predictors of sentinel lymph node metastasis in cutaneous melanoma patients using molecular and clinicopathologic high-risk features.”\n\nDecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node (SLN) positivity, independent of traditional staging factors.\n\nStudy methods and findings:\n\n\nFor 3,093 patients with T1-T4 cutaneous melanoma, authors used decision tree analysis to determine which molecular and clinicopathologic features best stratify SLN positivity risk.\n\n\nDecisionDx-Melanoma was the most important factor in distinguishing between high and low SLN-positivity rates (p","length":1935,"tagName":"div"}]